ProNAi Therapeutics Inc (DNAI) : Adams Street Partners reduced its stake in ProNAi Therapeutics Inc by 3.26% during the most recent quarter end. The investment management company now holds a total of 1,121,715 shares of ProNAi Therapeutics Inc which is valued at $5.4 Million after selling 37,831 shares in ProNAi Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.ProNAi Therapeutics Inc makes up approximately 0.99% of Adams Street Partners’s portfolio.
Other Hedge Funds, Including , Rs Investment Management Co boosted its stake in DNAI in the latest quarter, The investment management firm added 280,509 additional shares and now holds a total of 980,303 shares of ProNAi Therapeutics Inc which is valued at $4.8 Million. ProNAi Therapeutics Inc makes up approx 0.05% of Rs Investment Management Co’s portfolio. Comerica Bank added DNAI to its portfolio by purchasing 30,331 company shares during the most recent quarter which is valued at $147,105.Alps Advisors Inc reduced its stake in DNAI by selling 5,794 shares or 14.63% in the most recent quarter. The Hedge Fund company now holds 33,803 shares of DNAI which is valued at $163,945.Greenleaf Trust boosted its stake in DNAI in the latest quarter, The investment management firm added 1,682 additional shares and now holds a total of 192,494 shares of ProNAi Therapeutics Inc which is valued at $1.1 Million. ProNAi Therapeutics Inc makes up approx 0.03% of Greenleaf Trust’s portfolio.
ProNAi Therapeutics Inc opened for trading at $5.5 and hit $6.0699 on the upside on Friday, eventually ending the session at $5.82, with a gain of 8.38% or 0.45 points. The heightened volatility saw the trading volume jump to 6,08,945 shares. Company has a market cap of $175,619 M.
ProNAi Therapeutics Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Company’s lead DNAi product candidate PNT2258 treat cancers that overexpress BCL2 an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.